This Article Free upon publication Full Text Full Text (PDF) Correction Correction (v119,pe198) All Versions of this Article: 118/24/2649    most recent CIRCULATIONAHA.108.191100v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wharton, T. P. Search for Related Content PubMed PubMed Citation Articles by Wharton, T. P., Jr Related Collections Other Ethics and Policy Cardiovascular Pharmacology AHA Statements and Guidelines Catheter-based coronary and valvular interventions: other Acute myocardial infarction

(Circulation. 2008;118:2649-2661.)
© 2008 American Heart Association, Inc.

ACC/AHA Performance Measures

ACC/AHA 2008 Statement on Performance Measurement and Reperfusion Therapy

A Report of the ACC/AHA Task Force on Performance Measures (Work Group to Address the Challenges of Performance Measurement and Reperfusion Therapy)

WRITING COMMITTEE MEMBERS; Frederick A. Masoudi, MD, MSPH, FACC, Chair; Robert O. Bonow, MD, MACC, FAHA; Ralph G. Brindis, MD, MPH, FACC; Christopher P. Cannon, MD, FACC; Jo DeBuhr, RN, BSN; Susan Fitzgerald, RN, CCA; Paul A. Heidenreich, MD, FACC; Kalon K.L. Ho, MD, MSc, FACC, FAHA; Harlan M. Krumholz, MD, FACC, FAHA; Chris Leber, RN, BSN; David J. Magid, MD, MPH; David S. Nilasena, MD, MSPH, MS; John S. Rumsfeld, MD, PhD, FACC, FAHA; Sidney C. Smith, Jr, MD, FACC, FAHA; Thomas P. Wharton, Jr, MD, FACC

Key Words: ACC/AHA Performance Measures • performance measurement • reperfusion therapy • myocardial infarction • percutaneous coronary intervention • thrombolytic therapy

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 

Statement of Purpose...2650

1. Introduction...2650

2. History of the Time-to-Reperfusion Performance Measures...2650

3. Attributes of Performance Measures of Time to Reperfusion...2651

4. Specific Challenges to Measuring Time to Reperfusion...2652

   4.1. Measures Inclusions...2652

      4.1.1. Measures Inclusions—Work Group Conclusions...2653

   4.2. Measures Exclusions...2653

      4.2.1. Measures Exclusions—Work Group Conclusions...2654

   4.3. Time of Device Use for PCI...2654

      4.3.1. Time of Device Use for PCI: Work Group Conclusions...2655

5. Proposals for Future Measures of Time to Reperfusion...2655

   5.1. Time to Reperfusion Among Patients Transferred for PCI...2655

   5.2. Proportion of Reperfusion-Eligible Patients Receiving Therapy...2656

   5.3. Time From First Medical System Contact to Reperfusion...2656

   5.4. Time to Reperfusion for Patients Developing STEMI in the Hospital...2656

6. Future Considerations for Measuring Time to Reperfusion: Electronic Health Records and Clinical Registries...2657

7. Conclusions...2657

Appendix A. Inclusion and Exclusion Criteria for CMS and Joint Commission Reperfusion Measures...2658

Appendix B. Author Relationships With Industry and Other Entities...2658

Appendix C. Peer Reviewer Relationships With Industry and Other Entities...2659

References...2660

This document is an official document of the American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Performance Measures. The task force formed a work group to address the challenges of performance measurement and reperfusion therapy.

	1. Introduction

 
Acute reperfusion therapy, either with fibrinolytic therapy or percutaneous coronary intervention (PCI), is one of the most important treatments for patients with ST-segment elevation myocardial infarction (STEMI). Randomized clinical trials have shown that reperfusion therapy provided to eligible patients reduces the risk of death due to all causes.¹ The timeliness of reperfusion therapy is of central . . . [Full Text of this Article]

This article has been cited by other articles:

				A. R. Campbell, D. Satran, D. M. Larson, I. J. Chavez, B. T. Unger, B. P. Chacko, C. Kapsner, and T. D. Henry ST-Elevation Myocardial Infarction: Which Patients Do Quality Assurance Programs Include? Circ Cardiovasc Qual Outcomes, November 1, 2009; 2(6): 648 - 655. [Abstract] [Full Text] [PDF]